Clinical Trial Update: Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Realgar-Indigo Naturalis Formula (RIF) for non-high-risk acute promyelocytic leukemia is in early status (phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• Realgar-Indigo Naturalis Formula (realgar-indigo naturalis formula)

Snippet

Sponsor: First Affiliated Hospital Xi'an Jiaotong University | Conditions: Acute Promyelocytic Leukemia | Phase 3 | Status: UNKNOWN